Skip to main content
Caplight Logo









Normunity

Normunity

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://normunity.com/

Last Round

Series B

Jan 13, 2025

Est. Valuation

$500M

Total Funding Raised

$140M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Normunity is a biotechnology company that develops precision immuno-oncology therapies designed to restore the immune system's natural ability to identify and eliminate cancer cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immuno-oncologyt-cell engagersolid tumorsprecision medicinedrug discoverybiotechtumor microenvironmentclinical trialscancer immunotherapybiotechnologytherapeutic candidatesnovel drug mechanismsbiopharmapreclinical developmentpipeline development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Normunity Comparables

Compare Normunity with similar companies based on industry and business-model similarity.

Normunity comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Marengo Therapeutics
84%
Merck
81%
EvolveImmune
80%

Normunity Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 13, 2025
Series AOct 25, 2022

Key People

Founding team and executive leadership

Rachel W. Humphrey

President And Founding CEO

Founding Team

Normunity Investors

Notable investors and investment history

Normunity investors
InvestorRounds
Enavate SciencesSeries B
Connecticut InnovationsSeries B
Taiho VenturesSeries B, Series A
Osage University PartnersSeries B, Series A
Canaan PartnersSeries B, Series A
Pfizer VenturesSeries B
Sanofi VenturesSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors grew 36% MoM, reaching 2K.

  • Jul 26, 2026

    Monthly visitors grew 40% MoM, from 1K to 1.5K.

Normunity Filings

Explore SEC and related filing metadata, where available.

Normunity filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Normunity's valuation, stock price, and market status.

Is Normunity a public or private company?

Normunity is a private company.

What is the current stock price of Normunity?

Normunity is a private company with no public stock price. No recent secondary market data is available.

How much is Normunity worth (valuation)?

Normunity's valuation is estimated at $500.0M based on funding round data.

Can I buy Normunity stock?

Normunity shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Normunity's last funding round?

Normunity's most recent funding round was Series B on January 13, 2025.

Who are the main investors in Normunity?

Key investors in Normunity include Enavate Sciences, Samsara BioCapital.

Will Normunity IPO soon?

No public IPO plans have been announced for Normunity.

How can I track Normunity secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Normunity's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range26
Year Founded2020
Last FundingJan 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?